Cervical cancer patients frequently experience impaired quality of life (QoL) and treatment-related toxicities following chemoradiotherapy. This study assessed whether a dynamic integrated Chinese and Western medicine (CWM) intervention, guided by traditional Chinese medicine (TCM) syndrome differentiation, improves QoL and outcomes in these patients.

HER2 is expressed in a minority of patients with metastatic colorectal cancer (mCRC), yet it has proven to be a valuable therapeutic target for novel agents such as trastuzumab deruxtecan and tucatinib. Currently, testing is not mandatory in mCRC at baseline and a simple clinical tool to identify patients with a higher likelihood of being HER2-positive would be extremely helpful in guiding test requests and personalized medicine.

Nivolumab has become an essential therapeutic agent for patients with advanced or recurrent gastric cancer. However, the impact of metastatic patterns on its clinical efficacy has not been fully elucidated. This study aimed to clarify the association between distinct metastatic patterns and outcomes of nivolumab monotherapy.

Business intelligence (BI) solutions are nowadays offered as part of radiation oncology information systems (ROIS). They support state-of-the-art extraction of structured data for business and research use cases. The variety of use cases often comes with specific customizations for which IT experts are required. The involvement of the IT experts from the hospital data warehouse (DWH) or architecture teams adds value to secondary use of data in the line of good clinical practices (GCP). We summarize our experience implementing a BI module in a radiation oncology department, discuss key challenges, and give some recommendations for addressing them.

Eosinophil peroxidase (EPO) and myeloperoxidase (MPO) are large, cationic enzymes secreted by granulocytes that bind preferentially to negatively charged cancer cell membranes produced by the Warburg effect. In the presence of halide cofactors and hydrogen peroxide (H₂O₂), and under acidic conditions that potentiate catalysis, they generate singlet oxygen (¹O₂*), a metastable oxygen state whose microsecond lifetime defines its diffusion radius and therefore its cytotoxic target. This confines reactivity to enzyme-enriched cancer cell surfaces, producing a spatially restricted therapeutic effect [Supplementary Note 1].

Introduction The regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL), yet many patients relapse. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has shown promise in trials. This study investigates the real-world efficacy and safety of Pola-R-CHP versus R-CHOP. Methods We retrospectively analyzed 505 DLBCL patients treated at Peking Union Medical College Hospital between January 2011 and March 2025. Thirty-six patients received Pola-R-CHP; 36 matched R-CHOP patients were selected using 1:1 propensity score matching based on age, sex, subtype, stage, and IPI. Outcomes included interim and end-of-treatment response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Results Post-matching, 72 patients were included. Pola-R-CHP achieved higher interim CR (72.2% vs. 63.9%, P = 0.035) and ORR (100.0% vs. 83.3%, P = 0.011). At the end of treatment, CR was further improved (88.9% vs. 63.9%, P = 0.007), and ORR remained superior (100.0% vs. 86.1%, P = 0.020). At a median follow-up of 13.3 months (range, 1.1-141.9 months), 1 death and 2 progressions occurred in the Pola-R-CHP group compared with 9 deaths and 9 progressions in the R-CHOP group. Median OS and PFS were not reached in either cohort. At 12 months, the estimated OS was 97% for Pola-R-CHP and 94% for R-CHOP (P = 0.825), while the estimated PFS was 86% and 94%, respectively. This represented a numerical but not statistically significant difference (P = 0.457), likely reflecting the immature survival data and limited number of events at the time of analysis, rather than a true efficacy difference. Neutropenia was the most frequent adverse event (69.4%) and showed comparable severity between groups, while grade ≥3 AEs were numerically less frequent with Pola-R-CHP (8.3% vs. 13.9%, P = 0.453). Conclusion Pola-R-CHP achieved higher interim and end-of-treatment response rates than R-CHOP with a comparable safety profile. However, survival outcomes remain immature, and given the small matched sample size (n = 72), these findings should be interpreted cautiously and confirmed in larger prospective studies.

Hyperthermic intrathoracic chemotherapy (HITHOC) is an intraoperative treatment that involves the perfusion of heated chemotherapy agents within the thoracic cavity. Photodynamic therapy (PDT) utilizes systemically administered photosensitizing agents and targeted light exposure to eliminate residual cancer cells during the surgery. This study aimed to present our experience with local therapies in the management of pleural malignancies, describe the respective outcomes of each modality, and make a preliminary comparison.

Lung cancer prevalence is rising in Taiwan, with female gender and family history being key factors. This study evaluated the predictive capabilities of the PGS000070 polygenic risk score (PRS) model in Taiwanese populations, analyzing patient outcomes, pathology type, comorbidities, smoking history, and surgical procedures.

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characterized, particularly with respect to sex differences. Given the high prevalence of cardiovascular disease in patients with NSCLC, understanding potential sex-specific risks is critical.

The prognosis of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (EGFR-m-NSCLC) has improved with the introduction of oral EGFR- tyrosine kinase inhibitor (TKI). Lower adherence to oral anticancer medications is reportedly associated with a poor prognosis. It is important to understand the causes of lower adherence to oral anticancer medications. We aimed to assess the potential risk factors associated with low adherence to EGFR-TKIs in a real-world clinical setting using administrative claims data in Japan.

This is a perspective article with the aim to contextualize Halberstaedter's legacy and outline lessons for modern oncology, rather than to exhaustively review all literature. We revisit Prof. Ludwig Halberstaedter's 1928 report on the Radiology Institute at Charité Hospital in Berlin, Germany, marking its 25th anniversary with added historical and scientific context.

Abemaciclib (ABE) is a selective cyclin-dependent kinase 4/6 inhibitor widely used in breast cancer treatment. ABE inhibits renal tubular transporters, such as organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, thereby suppressing creatinine excretion. This leads to a reversible increase in serum creatinine (Scr) without causing true renal injury. Since Scr is commonly used to assess renal function and guide medication dose adjustments, this effect may influence the management of concomitant renally excreted drugs. We aimed to evaluate the impact of ABE-induced Scr changes on the dosing of concomitant renally excreted medications in real-world clinical practice.

Pancreatic adenocarcinoma (PDAC) is a disease process that carries high morbidity and mortality and is suspected to supplant colorectal cancer as the second leading cause of cancer-related death in the USA. Resectable disease is considered no tumor contact with the celiac axis, common hepatic artery, or superior mesenteric artery and less than 180-degrees contact with portal vein or superior mesenteric vein. The current standard of care for resectable disease is surgery.

Palbociclib and abemaciclib, CDK4/6 inhibitors with a shared primary mechanism of action, differ in their adverse effect profiles. We encountered several cases of switching between CDK4/6 inhibitors following treatment discontinuation owing to adverse events (AEs) in clinical practice.

B-cell maturation antigen-targeting bispecific antibodies such as teclistamab have been associated with increased risk of infections as compared with conventional treatment regimens. This study explored the efficacy of intravenous immunoglobulin (IVIG) prophylaxis in reducing infection-related hospitalizations (IRHs) in MM patients who underwent treatment with teclistamab.

Comprehensive cancer genome profiling (CGP) testing was approved in Japan in 2019, leading to increasing opportunities for CGP testing in elderly cancer patients. However, these patients may be unable to undergo treatment due to poor organ function. Therefore, we investigated the usefulness and challenges of CGP testing in elderly cancer patients.

Atezolizumab plus bevacizumab (AB) therapy is an effective systemic therapy for unresectable hepatocellular carcinoma (u-HCC). However, exacerbations of esophageal varices (EV) often occur, and EV management should be clarified to attain a better prognosis in patients with u-HCC. Our research aimed to explore the actual situation of EV exacerbation and its risk factors in patients receiving AB therapy.

This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS). The overall objective of this study was to identify the potential risks associated with osimertinib-induced adverse events.

The burden of androgen deprivation therapy (ADT) is only partially captured by legacy prostate cancer questionnaires, which devote few items to hormonal sequelae. Patient-Reported Evaluation of the Effects of Hormone Therapy (PREVES-HOR) is a 29-item, distress-anchored instrument developed to quantify ADT-specific physical, emotional, cognitive, sexual, and body image morbidity from a patient-centered, subjective perspective. We report the prespecified phase 1 psychometric evaluation.